


Concept Diagnostics

865 / SHREYANSH SAGARA / 39 Yrs / M / 176Cms. / 58Kgs. / Smoker

Heart Rate : 99 bpm / Tested On : 08-Jul-23 11:48:07 / HF 0.05 Hz - LF 35 Hz / Notch 50 Hz / Sn 1.00 Cm/mV / Sw 25 mm/s

ECG



Normal.

DR. PARTH THAKKAR
MD (Med.) / DrNB (Cardiology)
Interventional Cardiologist

Reported by: DR. ABHIMANYU KOTHARI



NAME	Mr. Shreyansh Sagara		
AGE/ SEX	39yrs / M	DATE	08/07/2023
REF. BY	Health Check Up	DONE BY	Dr. Parth Thakkar Dr. Abhimanyu Kothari

2D ECHO CARDIOGRAPHY & COLOR DOPPLER STUDY

FINDINGS:-

- Normal LV systolic function, LVEF=60%.
- No RWMA at rest
- LV and LA are of normal size.
- RA & RV are of normal size.
- Reduced LV Compliance
- Intact IAS & IVS.
- All Valves Are structurally Normal
- Trivial MR, No AR, No PR
- Trivial TR, No PAH, RVSP-25mmHg
- No clot or vegetation.
- No evidence of pericardial effusion.
- IVC is normal in size with preserved respiratory variation.



MEASUREMENTS:-

LVIDD	44(mm)	LA	27(mm)
LVIDS	26(mm)	AO	30(mm)
LVEF	60%	AV cusp	
IVSD / LVPWD	07/12(mm)	EPSS	

DOPPLER STUDY:-

Valve	Velocity (M/sec)	Max gradient (MmHg)	Mean gradient (Mm Hg)	Valve area Cm ²
Aortic	1.2	7.0		
Mitral	E: 0.7 A: 0.8			
Pulmonary	0.8	2.0		
Tricuspid	1.9	15		








CONCLUSION:-

- Normal LV systolic function, LVEF=60%.
- No RWMA at rest
- Normal LV Compliance
- All Valves Are structurally Normal
- Trivial MR, No AR, No PR
- Trivial TR, No PAH, RVSP-26mmHg
- IVC is normal in size with preserved respiratory variation.

Dr. Parth Thakkar
MD (Med.), DrNB (Cardiology)
Interventional Cardiologist
79901-79258




Dr. Abhimanyu D Kothari
MD (Med.), DM (Cardiology)
Interventional Cardiologist
9714675115



NAME :	SHREYANSH SAGARA	DATE :	08/07/2023
AGE/SEX:	39Y/M	REG.NO :	00
REFERRED BY: HEALTH CHECK UP			

X-RAY CHEST PA VIEW

- Fibro-calcified opacities noted in bilateral upper zones.
- No evidence of consolidation or active Koch's lesion seen.
- Heart size is within normal limit.
- Both CP angles are clear.
- Both dome of diaphragm appear normal.
- Bony thorax under vision appears normal.



Dr. VIDHI SHAH
MD RADIODIAGNOSIS

Dr. Vidhi Shah
M.D. Radiologist
G - 41469





NAME :	SHREYANSH SAGARA	DATE :	08/07/2023
AGE/SEX:	39Y/M	REG.NO :	00
REFERRED BY: HEALTH CHECK UP			

USG ABDOMEN

LIVER: normal in size & shows normal echotexture. No evidence of dilated IHBR. No evidence of focal or diffuse lesion. CBD & Portal vein appears normal.

GALL-

BLADDER: normal, No evidence of Gall Bladder calculi.

PANCREAS: appears normal in size & echotexture, No evidence of peri-pancreatic fluid collection.

SPLEEN: normal in size & shows normal echogenicity.

KIDNEYS: Right kidney measures 90 x 37 mm. Left kidney measures 97 x 51 mm. Both kidneys appear normal in size & echotexture. No evidence of calculus or hydronephrosis on either side.

URINARY

BLADDER: appears normal and shows normal distension & normal wall thickness. No evidence of calculus or mass lesion.

PROSTATE: normal in size & echotexture.

No evidence of Ascites.

No evidence of significant lymphadenopathy.

USG WITH HIGH FREQUENCY SOFT TISSUE PROBE:

Visualized bowel loops appears normal in caliber. No evidence of focal or diffuse wall thickening. No collection in RIF.



CONCLUSION:

➤ Normal USG abdomen.

Dr. VIDHI SHAH
MD RADIODIAGNOSIS

Dr. Vidhi Shah
M.D. Radiologist
G - 41469





R



SHREYANSH SAGARA 39Y/M M CHEST,FRN PA 08-Jul-23 11:06 AM
CONCEPT DIAGNOSTIC


TEST REPORT

Reg. No. : 307100153	Reg. Date : 08-Jul-2023 09:07	Ref.No :	Approved On : 08-Jul-2023 13:52
Name : Mr. SHREYANSH SAGARA			Collected On : 08-Jul-2023 09:48
Age : 39 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. : 9925505205
Location :			

Test	Results	Unit	Bio. Ref. Interval
Complete Blood Count			
Hemoglobin(SLS method)	15.7	g/dL	13.0 - 17.0
RBC Count(Ele.Impedence)	5.30	X 10 ¹² /L	4.5 - 5.5
Hematocrit (calculated)	47.4	%	40 - 50
MCV (Calculated)	89.4	fL	83 - 101
MCH (Calculated)	29.6	pg	27 - 32
MCHC (Calculated)	33.1	g/dL	31.5 - 34.5
RDW-CV	13.80	%	11.5 - 14.5
RDW-SD(calculated)	44.60	fL	36 - 46
Total WBC count	L 3740	/μL	4000 - 10000
DIFFERENTIAL WBC COUNT			
	[%]	EXPECTED VALUES	[Abs] EXPECTED VALUES
Neutrophils	69	38 - 70	2581 /cmm 1800 - 7700
Lymphocytes	25	21 - 49	L 935 /cmm 1000 - 3900
Eosinophils	1	0 - 7	37 /cmm 20 - 500
Monocytes	5	3 - 11	L 187 /cmm 200 - 800
Basophils	0	0 - 2	0 /cmm 0 - 100
NLR (Neutrophil: Lymphocyte Ratio)	2.76		1.1 - 3.5
Platelet Count (Ele.Impedence)	183000	/cmm	150000 - 410000
PCT	0.18	ng/mL	< 0.5
MPV	11.90	fL	6.5 - 12.0
ESR	3	mm/hr	17-50 Yrs : <12, 51-60 Yrs : <19, 61-70 Yrs : <20, >70 Yrs : <30

Test done from collected sample.

This is an electronically authenticated report.

Approved by: Dr. Mohan Galande

M.D. Pathology
G-10116

Page 1 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 13:52

TEST REPORT

Reg. No. : 307100153 Reg. Date : 08-Jul-2023 09:07 Ref.No : Approved On : 08-Jul-2023 15:59
Name : Mr. SHREYANSH SAGARA Collected On : 08-Jul-2023 09:48
Age : 39 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
BLOODGROUP & RH			
<u>Specimen: EDTA and Serum; Method: Gel card system</u>			
Blood Group "ABO" <i>Agglutination</i>	"B"		
Blood Group "Rh" <i>Agglutination</i>	Positive		
EDTA Whole Blood			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S.,D.C.P(Patho)
G- 22475

Page 2 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 15:59

TEST REPORT

Reg. No. : 307100153 Reg. Date : 08-Jul-2023 09:07 Ref.No : Approved On : 08-Jul-2023 14:51
Name : Mr. SHREYANSH SAGARA Collected On : 08-Jul-2023 09:48
Age : 39 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
FASTING PLASMA GLUCOSE <i>Hexokinase</i>	77.06	mg/dL	Normal: <=99.0 Prediabetes: 100-125 Diabetes :>=126

Plasma

Criteria for the diagnosis of diabetes:

- HbA1c >= 6.5 *
Or
- Fasting plasma glucose >126 gm/dL. Fasting is defined as no caloric intake at least for 8 hrs.
Or
- Two hour plasma glucose >= 200mg/dL during an oral glucose tolerance test by using a glucose load containing equivalent of 75 gm anhydrous glucose dissolved in water.
Or
- In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >= 200 mg/dL. *In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing. American diabetes association. Standards of medical care in diabetes 2011. Diabetes care 2011;34;S11.

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S,D.C.P(Patho)
G- 22475

Page 3 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 14:51

TEST REPORT

Reg. No. : 307100153 Reg. Date : 08-Jul-2023 09:07 Ref.No : Approved On : 08-Jul-2023 14:50
Name : Mr. SHREYANSH SAGARA Collected On : 08-Jul-2023 12:24
Age : 39 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
POST PRANDIAL PLASMA GLUCOSE Specimen: Fluoride plasma			
POST PRANDIAL PLASMA GLUCOSE <i>Hexokinase</i>	161.92	mg/dL	Normal: <=139 Prediabetes : 140-199 Diabetes: >=200
Plasma			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S.,D.C.P(Patho)
G- 22475

Page 4 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 14:50

TEST REPORT

Reg. No. : 307100153 Reg. Date : 08-Jul-2023 09:07 Ref.No : Approved On : 08-Jul-2023 14:50
Name : Mr. SHREYANSH SAGARA Collected On : 08-Jul-2023 09:48
Age : 39 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
GGT	H 79.6	U/L	10 - 71
<i>L-Y-Glutamyl-3 Carboxy-4-Nitroanilide, Enzymetic Colorimetric</i>			
Serum			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S.,D.C.P(Patho)
G- 22475

Page 5 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 14:50

TEST REPORT

Reg. No. : 307100153	Reg. Date : 08-Jul-2023 09:07	Ref.No :	Approved On : 08-Jul-2023 14:50
Name : Mr. SHREYANSH SAGARA			Collected On : 08-Jul-2023 09:48
Age : 39 Years	Gender : Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. : 9925505205
Location :			

Test Name	Results	Units	Bio. Ref. Interval
LIPID PROFILE			
CHOLESTEROL	254.00	mg/dL	Desirable <=200 Borderline high risk 200 - 240 High Risk >240
TRIGLYCERIDE <i>Enzymatic Colorimetric Method</i>	H 209.00	mg/dL	<150 : Normal, 150-199 : Border Line High, 200-499 : High, >=500 : Very High
VLDL	H 42	mg/dL	0 - 30
LDL CHOLESTEROL <i>Calculated Method</i>	110.03	mg/dL	< 100 : Optimal, 100-129 : Near Optimal/above optimal, 130-159 : Borderline High, 160-189 : High, >=190 : Very High
HDL-CHOLESTEROL	101.97	mg/dL	<40 >60
CHOL/HDL RATIO	2.49		0.0 - 3.5
LDL/HDL RATIO	1.08		1.0 - 3.4
TOTAL LIPID	886.00	mg/dL	400 - 1000
Serum			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S,D.C.P(Patho)
G- 22475

Page 6 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 14:50

TEST REPORT

Reg. No. : 307100153	Reg. Date : 08-Jul-2023 09:07	Ref.No :	Approved On : 08-Jul-2023 14:51
Name : Mr. SHREYANSH SAGARA			Collected On : 08-Jul-2023 09:48
Age : 39 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. : 9925505205
Location :			

Test Name	Results	Units	Bio. Ref. Interval
<u>LIVER FUNCTION TEST</u>			
TOTAL PROTEIN	7.48	g/dL	6.6 - 8.8
ALBUMIN	5.12	g/dL	3.5 - 5.2
GLOBULIN <i>(Calculated)</i>	L 2.36	g/dL	2.4 - 3.5
ALB/GLB <i>(Calculated)</i>	2.17		1.2 - 2.2
SGOT	47.20	U/L	<35
SGPT	25.30	U/L	<41
ALK. PHOSPHATASE <i>ENZYMATIC COLORIMETRIC IFCC, PNP, AMP BUFFER</i>	119.80	U/L	40 - 130
TOTAL BILIRUBIN	1.21	mg/dL	0.1 - 1.2
DIRECT BILIRUBIN	0.36	mg/dL	<0.2
INDIRECT BILIRUBIN <i>Calculated.</i>	0.85	mg/dL	0.0 - 1.00
Serum			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: **Dr. Keyur Patel**

M.B.B.S.,D.C.P(Patho)
G- 22475

Page 7 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 14:51

TEST REPORT

Reg. No. : 307100153 **Reg. Date** : 08-Jul-2023 09:07 **Ref.No** : **Approved On** : 08-Jul-2023 16:45
Name : Mr. SHREYANSH SAGARA **Collected On** : 08-Jul-2023 09:48
Age : 39 Years **Gender**: Male **Pass. No.** : **Dispatch At** :
Ref. By : APOLLO **Tele No.** : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
HEMOGLOBIN A1 C ESTIMATION			
Specimen: Blood EDTA			
HbA1c <i>High Performance Liquid Chromatography (HPLC)</i>	5.00	%	Normal: <= 5.6 Prediabetes: 5.7-6.4 Diabetes: >= 6.5 6-7 : Near Normal Glycemia, <7 : Goal , 7-8 : Good Control , >8 : Action Suggested.
Mean Blood Glucose <i>(Calculated)</i>	97	mg/dL	
Sample Type: EDTA Whole Blood			

Criteria for the diagnosis of diabetes

- HbA1c ≥ 6.5 * Or Fasting plasma glucose >126 gm/dL. Fasting is defined as no caloric intake at least for 8 hrs. Or
- Two hour plasma glucose ≥ 200 mg/dL during an oral glucose tolerance test by using a glucose load containing equivalent of 75 gm anhydrous glucose dissolved in water. Or
- In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dL. *In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing. American diabetes association. Standards of medical care in diabetes 2011. Diabetes care 2011:34:S11.

Limitation of HbA1c

- In patients with Hb variants even analytically correct results do not reflect the same level of glycemic control that would be expected in patients with normal population.
 - Any cause of shortened erythrocyte survival or decreased mean erythrocyte survival or decreased mean erythrocyte age eg. hemolytic diseases, pregnancy, significant recent/chronic blood loss etc. will reduce exposure of RBC to glucose with consequent decrease in HbA1c values.
 - Glycated HbF is not detected by this assay and hence specimens containing high HbF ($>10\%$) may result in lower HbA1c values than expected. Importance of HbA1C (Glycated Hb.) in Diabetes Mellitus
- HbA1C, also known as glycated hemoglobin, is the most important test for the assessment of long term blood glucose control (also called glycemic control).
 - HbA1C reflects mean glucose concentration over past 6-8 weeks and provides a much better indication of long term glycemic control than blood glucose determination.
 - HbA1c is formed by non-enzymatic reaction between glucose and Hb. This reaction is irreversible and therefore remains unaffected by short term fluctuations in blood glucose levels.
 - Long term complications of diabetes such as retinopathy (Eye-complications), nephropathy (kidney-complications) and neuropathy (nerve complications), are potentially serious and can lead to blindness, kidney failure, etc.
 - Glycemic control monitored by HbA1c measurement using HPLC method (GOLD STANDARD) is considered most important. (Ref. National Glycohemoglobin Standardization Program - NGSP)

Test done from collected sample.

This is an electronically authenticated report.



Approved by: **Dr. Avani Patel**

M.D. Biochemistry Page 8 of 15
Reg No.- G-34103

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 16:45

TEST REPORT

Reg. No. : 307100153	Reg. Date : 08-Jul-2023 09:07	Ref.No :	Approved On : 08-Jul-2023 16:45
Name : Mr. SHREYANSH SAGARA			Collected On : 08-Jul-2023 09:48
Age : 39 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. : 9925505205
Location :			

Bio-Rad CDM System
Bio-Rad Variant V-II Instrument #1

PATIENT REPORT
V2TURBO_A1c_2.0

Patient Data

Sample ID: 130703500114
 Patient ID:
 Name:
 Physician:
 Sex:
 DOB:

Analysis Data


Analysis Performed: 08/07/2023 16:34:54
 Injection Number: 8201
 Run Number: 332
 Rack ID:
 Tube Number: 7
 Report Generated: 08/07/2023 16:38:49
 Operator ID:

Comments:

Peak Name	NGSP %	Area %	Retention Time (min)	Peak Area
A1a	---	1.1	0.162	17655
A1b	---	0.6	0.227	9456
F	---	1.0	0.274	15672
LA1c	---	1.5	0.404	24144
A1c	5.0	---	0.513	65911
P3	---	3.3	0.784	50842
P4	---	1.2	0.860	18994
Ao	---	87.0	0.981	1357173

Total Area: 1,559,848

HbA1c (NGSP) = 5.0 %



Test done from collected sample.

This is an electronically authenticated report.



Dr. Avani Patel
Approved by: Dr. Avani Patel

M.D. Biochemistry Page 9 of 15
Reg No.- G-34103

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 16:45

TEST REPORT

Reg. No. : 307100153	Reg. Date : 08-Jul-2023 09:07	Ref.No :	Approved On : 08-Jul-2023 15:36
Name : Mr. SHREYANSH SAGARA			Collected On : 08-Jul-2023 09:48
Age : 39 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. : 9925505205
Location :			

Test Name	Results	Units	Bio. Ref. Interval
THYROID FUNCTION TEST			
T3 (triiodothyronine)	0.66	ng/mL	0.6 - 1.52
T4 (Thyroxine) <small>CMIA</small>	5.50	µg/dL	5.5 - 11.0
TSH (ultra sensitive) <small>CMIA</small>	3.096	µIU/mL	0.35 - 4.94

Sample Type: Serum**Comments:**

Thyroid stimulating hormone (TSH) is synthesized and secreted by the anterior pituitary in response to a negative feedback mechanism involving concentrations of FT3 (free T3) and FT4 (free T4). Additionally, the hypothalamic tripeptide, thyrotropin-releasing hormone (TRH), directly stimulates TSH production. TSH stimulates thyroid cell production and hypertrophy, also stimulate the thyroid gland to synthesize and secrete T3 and T4. Quantification of TSH is significant to differentiate primary (thyroid) from secondary (pituitary) and tertiary (hypothalamus) hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

TSH levels During Pregnancy :

- First Trimester : 0.1 to 2.5 µIU/mL
- Second Trimester : 0.2 to 3.0 µIU/mL
- Third trimester : 0.3 to 3.0 µIU/mL

Reference : Carl A.Burtis,Edward R.Ashwood,David E.Bruns. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th Edition. Philadelphia: WB Saunders,2012:2170

Test done from collected sample.

This is an electronically authenticated report.

**Approved by: Dr. Avani Patel**M.D. Biochemistry Page 10 of 15
Reg No.- G-34103**Generated On :** 08-Jul-2023 16:44**Approved On:** 08-Jul-2023 15:36

TEST REPORT

Reg. No. : 307100153 **Reg. Date** : 08-Jul-2023 09:07 **Ref.No** : **Approved On** : 08-Jul-2023 15:34
Name : Mr. SHREYANSH SAGARA **Collected On** : 08-Jul-2023 09:48
Age : 39 Years **Gender:** Male **Pass. No. :** **Dispatch At** :
Ref. By : APOLLO **Tele No.** : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
-----------	---------	-------	--------------------

PSA	1.127	ng/mL	0 - 4
-----	-------	-------	-------

CMIA

Sample Type: Serum**Useful For**

- Evaluating patients with documented prostate problems in whom multiple prostate-specific antigen tests may be necessary per year
- Monitoring patients with a history of prostate cancer as an early indicator of recurrence and response to treatment.
- Prostate cancer screening.

Comments

-Prostate-specific antigen (PSA) is a glycoprotein that is produced by the prostate gland, the lining of the urethra, and the bulbourethral gland. Normally, very little PSA is secreted in the blood. Increases in glandular size and tissue damage caused by benign prostatic hypertrophy, prostatitis, or prostate cancer may increase circulating PSA levels.

-Digital rectal examination generally does not increase normal prostate-specific antigen (PSA) values. However, cystoscopy, urethral instrumentation, and prostate biopsy may increase PSA levels.

Test done from collected sample.

This is an electronically authenticated report.

**Approved by:** Dr. Avani PatelM.D. Biochemistry Page 11 of 15
Reg No.- G-34103**Generated On :** 08-Jul-2023 16:44**Approved On:** 08-Jul-2023 15:34

TEST REPORT

Reg. No. : 307100153	Reg. Date : 08-Jul-2023 09:07	Ref.No :	Approved On : 08-Jul-2023 14:38
Name : Mr. SHREYANSH SAGARA			Collected On : 08-Jul-2023 09:48
Age : 39 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. : 9925505205
Location :			

Test Name	Results	Units	Bio. Ref. Interval
<u>URINE ROUTINE EXAMINATION</u>			
<u>Physical Examination</u>			
Colour	Pale Yellow		
Clarity	Clear		
<u>CHEMICAL EXAMINATION (by strip test)</u>			
pH	6.0		4.6 - 8.0
Sp. Gravity	1.020		1.002 - 1.030
Protein	Nil		Absent
Glucose	Nil		Absent
Ketone	Nil		Absent
Bilirubin	Nil		Nil
Nitrite	Negative		Nil
<u>MICROSCOPIC EXAMINATION</u>			
Leucocytes (Pus Cells)	1-2		0 - 5/hpf
Erythrocytes (RBC)	5-6		0 - 5/hpf
Casts	Nil	/hpf	Absent
Crystals	Nil		Absent
Epithelial Cells	Nil		Nil
Monilia	Nil		Nil
T. Vaginalis	Nil		Nil
Urine			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S.,D.C.P(Patho)
G- 22475

Page 12 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 14:38

TEST REPORT

Reg. No. : 307100153 Reg. Date : 08-Jul-2023 09:07 Ref.No : Approved On : 08-Jul-2023 14:51
Name : Mr. SHREYANSH SAGARA Collected On : 08-Jul-2023 09:48
Age : 39 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
CREATININE	1.03	mg/dL	0.67 - 1.5

Serum

Creatinine is the most common test to assess kidney function. Creatinine levels are converted to reflect kidney function by factoring in age and gender to produce the eGFR (estimated Glomerular Filtration Rate). As the kidney function diminishes, the creatinine level increases; the eGFR will decrease. Creatinine is formed from the metabolism of creatine and phosphocreatine, both of which are principally found in muscle. Thus the amount of creatinine produced is, in large part, dependent upon the individual's muscle mass and tends not to fluctuate much from day-to-day. Creatinine is not protein bound and is freely filtered by glomeruli. All of the filtered creatinine is excreted in the urine.

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S.,D.C.P(Patho)
G- 22475

Page 13 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 14:51

TEST REPORT

Reg. No. : 307100153 **Reg. Date** : 08-Jul-2023 09:07 **Ref.No** : **Approved On** : 08-Jul-2023 14:51
Name : Mr. SHREYANSH SAGARA **Collected On** : 08-Jul-2023 09:48
Age : 39 Years **Gender**: Male **Pass. No.** : **Dispatch At** :
Ref. By : APOLLO **Tele No.** : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
UREA	20.1	mg/dL	17 - 43

Serum

Useful screening test for evaluation of kidney function. Urea is the final degradation product of protein and amino acid metabolism. In protein catabolism, the proteins are broken down to amino acids and deaminated. The ammonia formed in this process is synthesized to urea in the liver. This is the most important catabolic pathway for eliminating excess nitrogen in the human body. Increased blood urea nitrogen (BUN) may be due to prerenal causes (cardiac decompensation, water depletion due to decreased intake and excessive loss, increased protein catabolism, and high protein diet), renal causes (acute glomerulonephritis, chronic nephritis, polycystic kidney disease, nephrosclerosis, and tubular necrosis), and postrenal causes (eg, all types of obstruction of the urinary tract, such as stones, enlarged prostate gland, tumors). The determination of serum BUN currently is the most widely used screening test for the evaluation of kidney function. The test is frequently requested along with the serum creatinine test since simultaneous determination of these 2 compounds appears to aid in the differential diagnosis of prerenal, renal and postrenal hyperuremia.

Test done from collected sample.

This is an electronically authenticated report.

**Approved by: Dr. Keyur Patel**M.B.B.S.,D.C.P(Patho)
G- 22475

Page 14 of 15

Generated On : 08-Jul-2023 16:44**Approved On:** 08-Jul-2023 14:51

TEST REPORT

Reg. No. : 307100153 **Reg. Date** : 08-Jul-2023 09:07 **Ref.No** : **Approved On** : 08-Jul-2023 11:21
Name : Mr. SHREYANSH SAGARA **Collected On** : 08-Jul-2023 09:48
Age : 39 Years **Gender**: Male **Pass. No.** : **Dispatch At** :
Ref. By : APOLLO **Tele No.** : 9925505205
Location :

Test Name	Results	Units	Bio. Ref. Interval
<u>ELECTROLYTES</u>			
Sodium (Na+) <small>ISE</small>	144.2	mmol/L	136 - 145
Potassium (K+) <small>ISE</small>	4.5	mmol/L	3.5 - 5.1
Chloride(Cl-) <small>ISE</small>	104.2	mmol/L	98 - 107
Serum			

Comments

The electrolyte panel is ordered to identify electrolyte, fluid, or pH imbalance. Electrolyte concentrations are evaluated to assist in investigating conditions that cause electrolyte imbalances such as dehydration, kidney disease, lung diseases, or heart conditions. Repeat testing of the electrolyte or its components may be used to monitor the patient's response to treatment of any condition that may be causing the electrolyte, fluid or pH imbalance.

----- End Of Report -----

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S.,D.C.P(Patho)
G- 22475

Page 15 of 15

Generated On : 08-Jul-2023 16:44

Approved On: 08-Jul-2023 11:21